Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients
Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients
The purpose of this study is to prospectively evaluate the impact of sleep apnea on the
 cardiovascular morbidity and mortality of patients with end-stage renal disease.
Sleep apnea is more prevalent in end stage renal disease patients than in the general
 population, and may participate to the increased cardiovascular mortality observed in this
 group of patients. Despite a significant increase in knowledge about the harmful effects of
 obstructive sleep apnea in the general population, the prognostic impact of sleep apnea in
 the end stage renal disease population has not yet been investigated.

 The purpose of this trial is to investigate the hypothesis that moderate to severe sleep
 apnea increase the risk of major cardiovascular events in patients with end stage renal
 disease.

 The severity of sleep apnea is measured at inclusion and the patients are followed during 3
 years to assess the cardiovascular end-points. The result of the sleep study is communicated
 to the treating physician and the decision whether to treat or not sleep apnea is left to the
 treating physician, independently of the study protocol. The comparison will include three
 groups: patients without sleep apnea, untreated patients with moderate to severe sleep apnea
 and treated patients with sleep apnea.
Inclusion Criteria:

 -  end stage renal disease on renal replacement therapy

 -  age ≥ 18 years

 Exclusion Criteria:

 -  unstable congestive heart failure

 -  active psychiatric disease